IMPL vs. TFFP, VYNE, AIMD, RVLP, VCNX, NRBO, AKTX, BCEL, AEZS, and KTTA
Should you be buying Impel Pharmaceuticals stock or one of its competitors? The main competitors of Impel Pharmaceuticals include TFF Pharmaceuticals (TFFP), VYNE Therapeutics (VYNE), Ainos (AIMD), RVL Pharmaceuticals (RVLP), Vaccinex (VCNX), NeuroBo Pharmaceuticals (NRBO), Akari Therapeutics (AKTX), Atreca (BCEL), Aeterna Zentaris (AEZS), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
Impel Pharmaceuticals vs.
Impel Pharmaceuticals (NASDAQ:IMPL) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
TFF Pharmaceuticals has lower revenue, but higher earnings than Impel Pharmaceuticals.
TFF Pharmaceuticals received 56 more outperform votes than Impel Pharmaceuticals when rated by MarketBeat users. Likewise, 67.35% of users gave TFF Pharmaceuticals an outperform vote while only 52.63% of users gave Impel Pharmaceuticals an outperform vote.
Impel Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
Impel Pharmaceuticals currently has a consensus target price of $19.67, suggesting a potential upside of 3,638.91%. TFF Pharmaceuticals has a consensus target price of $5.50, suggesting a potential upside of 1,475.93%. Given Impel Pharmaceuticals' higher probable upside, analysts clearly believe Impel Pharmaceuticals is more favorable than TFF Pharmaceuticals.
Impel Pharmaceuticals has a net margin of -480.74% compared to TFF Pharmaceuticals' net margin of -3,403.80%. Impel Pharmaceuticals' return on equity of 0.00% beat TFF Pharmaceuticals' return on equity.
In the previous week, Impel Pharmaceuticals had 1 more articles in the media than TFF Pharmaceuticals. MarketBeat recorded 1 mentions for Impel Pharmaceuticals and 0 mentions for TFF Pharmaceuticals. Impel Pharmaceuticals' average media sentiment score of 0.00 equaled TFF Pharmaceuticals'average media sentiment score.
73.9% of Impel Pharmaceuticals shares are held by institutional investors. Comparatively, 17.7% of TFF Pharmaceuticals shares are held by institutional investors. 6.2% of Impel Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of TFF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Impel Pharmaceuticals beats TFF Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Impel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMPL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Impel Pharmaceuticals Competitors List
Related Companies and Tools
